Crossmark

Clinical practice and metabolic consequences of olanzapine use in schizophrenia: results from a national survey in Spain

Published Print: 2025-10

Authors

Muñoz-Manchado, L.I. https://orcid.org/0000-0002-3742-4435
Bernardo, M. https://orcid.org/0000-0001-8748-6717
Villagrán-Moreno, J.M. https://orcid.org/0000-0003-3033-3298
Fernández-Egea, E. https://orcid.org/0000-0003-4128-8955
Funding

Funding for this research was provided by:

NIHR Cambridge Biomedical Research Centre (NIHR203312)

Medical Research Council

National Institute on Handicapped Research (MR/W029987/1)
License Information

Text and Data Mining valid from 2025-10-01

Text and Data Mining valid from 2025-10-01
More Information

This article is maintained by: Elsevier

Article Title: Clinical practice and metabolic consequences of olanzapine use in schizophrenia: results from a national survey in Spain

Journal Title: The European Journal of Psychiatry

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ejpsy.2025.100323

Content Type: article

Copyright: © 2025 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Psiquiatría y Salud Mental.

Document is current